G. Clare Kahn was appointed Director of Stoke Therapeutics, Inc. As of November 6, 2026, Stoke Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 7, 2026 to September 25, 2026, naming 1 appointment (Form 8-K, April 7, 2026).
Who owns Stoke Therapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Stoke Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Stoke Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-07 to 2026-09-25. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Stoke Therapeutics, Inc. files it.
Also on the record for Stoke Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.5% of the class | 5%+ stakes | Source |
| September 30, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 5.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 6.5% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by The Toronto-Dominion Bank | 4.9% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.5% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 8.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Wellington Management Group LLP | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 6.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by The Toronto-Dominion Bank | 5.4% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Stoke Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Stoke Therapeutics, Inc. and the records around it.
Stoke Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Cowen Financial Products LLC also filed stake reports on 1 other company: UroGen Pharma Ltd. (Nov 2025)
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), UroGen Pharma Ltd. (Aug 2026), Immatics N.V. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Watch Stoke Therapeutics, Inc.
Get an email when Stoke Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Stoke Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Stoke Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Stoke Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-25 | Reported | not named in the filing | 8-K, 2026-09-25 | ||
| 2026-04-07 | In | Director | 8-K, 2026-04-07 |
Who leads Stoke Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: G. Clare Kahn, appointed (filed 2026-04-07).
New leaders reset buying decisions — get the Full Report on Stoke Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Stoke Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Stoke Therapeutics, Inc.Every change, in the filing's words
Reported
(b) On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the "Board") of Stoke Therapeutics, Inc. (the "Company") of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026.
- Dr. Kaye's resignation was not the result of any disagreement with the Company.
- (d) On September 23, 2026, the Board, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Alexander (Bo) Cumbo to serve on the Board as a Class III director, effective September 23, 2026, to fill the vacancy created by Dr. Kaye's resignation.
- Mr. Cumbo shall hold office for a term expiring at the 2028 Annual Meeting of Stoke's stockholders, which is the next stockholder meeting at which Class III directors will be elected.
- In connection with his appointment to the Board, and in accordance with the Company's non-employee director compensation program (the "Director Compensation Program"), Mr. Cumbo will receive an annual cash retainer of $45,000 for service on the Board.
- In addition, in accordance with the Company's 2019 Equity Incentive Plan (the "Plan"), on the effective date of his appointment, Mr. Cumbo was granted an initial stock option to purchase 39,674 shares of the Company's common stock, which represents a target grant date fair value of approximately $724,000 as calculated in accordance with ASC 718, and will vest in twelve substantially equal quarterly installments on each quarterly anniversary of the date of grant.
Appointed: G. Clare Kahn, Director
(d) On April 3, 2026, the Board of Directors (the "Board") of Stoke Therapeutics, Inc. ("Stoke" or the "Company"), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective immediately, to fill the vacancy created by the increase in Board size.
- Dr. Kahn shall hold office for a term expiring at the 2026 Annual Meeting of Stoke's stockholders, which is the next stockholder meeting at which Class I directors will be elected.
- Dr. Kahn was also appointed to serve on the Nominating and Corporate Governance Committee of the Board and as the chairperson of the Research and Development Committee of the Board, effective as of the date of her appointment.
- In connection with her appointment to the Board, and in accordance with the Company's non-employee director compensation program (the "Director Compensation Program"), Dr. Kahn will receive an annual cash retainer of $45,000 for service on the Board.
- In addition, in accordance with the Company's 2019 Equity Incentive Plan (the "Plan"), on the effective date of her appointment, Dr. Kahn was granted an initial stock option to purchase 30,782 shares of the Company's common stock, which represents a target grant date fair value of approximately $724,000 as calculated in accordance with ASC 718, and will vest in twelve substantially equal quarterly installments on each quarterly anniversary of the date of grant.
Tools for this story
Each opens in a new tab, filled in for Stoke Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.